US2014135399A1PendingUtilityA1

Novel polymorphs and salts

65
Assignee: CHIESI FARMA SPAPriority: Apr 1, 2010Filed: Jan 23, 2014Published: May 15, 2014
Est. expiryApr 1, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Fausto PivettiMaurizio DelcanaleStefano Luca GiaffredaMarco Curzi
A61K 9/0053C07C 61/40C07C 279/14C07C 229/26A61K 31/19C07C 2601/02C07B 2200/13A61K 31/192A61P 25/28
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel polymorphic forms and salts of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled) 
     
     
         8 . A salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid selected from the group consisting of
 Na salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid; 
 K salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid; 
 Ca salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid; 
 L-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl(cyclopropanecarboxylic acid; 
 D-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid; and 
 L-Lysine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
 
     
     
         9 . (canceled) 
     
     
         10 . A pharmaceutical composition, comprising a substantially pure salt according to  claim 8 , and a pharmaceutically acceptable carrier. 
     
     
         11 . (canceled) 
     
     
         12 . A method of the treatment or prophylaxis of Alzheimer's Disease, comprising administering to a subject in need thereof an effective amount of a salt according to  claim 8 . 
     
     
         13 . A pharmaceutical composition according to  claim 10 , which comprises Na salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         14 . A pharmaceutical composition according to  claim 10 , which comprises K salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         15 . A pharmaceutical composition according to  claim 10 , which comprises Ca salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         16 . A pharmaceutical composition according to  claim 10 , which comprises L-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         17 . A pharmaceutical composition according to  claim 10 , which comprises D-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         18 . A pharmaceutical composition according to  claim 10 , which comprises L-Lysine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         19 . A method to  claim 12 , which comprises administering Na salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         20 . A method to  claim 12 , which comprises administering K salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         21 . A method to  claim 12 , which comprises administering Ca salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         22 . A method to  claim 12 , which comprises administering L-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         23 . A method to  claim 12 , which comprises administering D-Arginine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid. 
     
     
         24 . A method to  claim 12 , which comprises administering L-Lysine salt of 1-(3′,4′-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid.

Join the waitlist — get patent alerts

Track US2014135399A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.